Oxford Brookes University
Oxford, Oxfordshire, OX3 0BP, United Kingdom
NCT Number: NCT05623696
The purpose of this study is to see if the front part of the brain called the "Dorsolateral Prefrontal Cortex" (DLPFC) has a role in our ability to feel breathlessness. The experiment will use a device that sits on the top of the head which produces a magnetic field that penetrates the scalp and excites the brain tissue directly under it. This procedure is called repetitive transcranial magnetic stimulation (rTMS), it is a painless procedure and known to be safe in healthy individuals. Previous research has shown that the pain felt when capsaicin, the active ingredient in 'chilli' powder, is applied to the hand is reduced by applying the rTMS on the scalp directly above the DLPFC part of the brain. In this experiment we want to see if breathlessness is also reduced. We will use a breathing task that will generate a moderate amount of breathlessness by adding a small amount of carbon dioxide to the inhaled air, while preventing the increase in the amount of breathing we would normally see in response to this. If we find that breathlessness produced by this breathing task is reduced after rTMS over the DLPFC, this may lead to new drugs that target this part of the brain in patients suffering from breathlessness due to heart or lung disease. The study will also improve our knowledge of how the brain enables us to feel breathlessness
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Oxford, Oxfordshire, OX3 0BP, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
healthy individuals, over 18 years old, with no history of heart, lung or neurological conditions
Exclusion criteria
5 Hz rTMS applied using an actual coil over the left DLPFC
5Hz rTMS applied using actual coil over Right DLPFC
5Hz rTMS applied using sham coil over left or right DLPFC
Time frame: Average of 4 steady state ratings in the last minute of air hunger tests
Ratings of air hunger on a 100mm Visual analog scale with the extremes defined as 'non' and 'tolerable limit'
Time frame: Questionnaire administered immediately following pre and post intervention air hunger tests for how participants were feeling at that moment in time.
Ratings provided on a 100mm visual analogue scale anchored by a negative mood descriptor at one extreme and the opposing positive mood descriptor at the other extreme. The average scores for 'sedation' descriptors, 'discontentment' descriptors, and 'relaxation' descriptors are each expressed as %maximum
Time frame: Form Y-2 (trait anxiety) administered once on the initial practice day. Form Y-1 (state anxiety) administered immediately following pre and post intervention air hunger tests on test days.
20 is the lowest score and 80 is the highest score for both state (form Y-1) and trait (Form Y-2) anxiety
Time frame: Administered immediately following pre and post intervention air hunger tests in relation to the "test just completed"
For Total score; zero indicates no dyspnoea and 36 indicates worst possible dyspnoea (expressed as %fullscale).
For Physical score; zero indicates no dyspnoea in the physical domain and 21 indicates worst possible dyspnoea in physical domain (expressed as %fullscale).
For Emotion score; zero indicates no dyspnoea in emotion domian and 15 indicates worst possible dyspnoea in emotion domain (expressed as %fullscale).
Oxford Brookes University
Other
Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Dorsolateral Prefrontal Cortex (DLPFC) on Hypercapnic Air Hunger Induced in Healthy Individuals.
Acronym: AHrTMS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05352490
Decompensated Heart Failure ; COPD Exacerbation, Dyspnea
Monastir, Tunisia
View Trial DetailsNCT04886128
Acute Heart Failure, Cardiovascular Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT07228676
Dyspnea, Oxygen
Poitiers, France
View Trial DetailsNCT05412160
Amino Acid Metabolism, Inborn Errors, Argininemia
Milan, Italy
View Trial Details